Anti-BP230 high-affinity monoclonal antibody and application thereof

By sorting and recombinantly expressing anti-BP230 monoclonal antibodies in New Zealand white rabbits, the problem of failure to effectively prepare anti-BP230 antibodies in the prior art was solved, efficient diagnosis and treatment of BP diseases were achieved, and fast and accurate detection methods were provided. .

CN118978592AActive Publication Date: 2024-11-19SUZHOU FANGKE BIOTECHNOLOGY CO LTD +2
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410793016.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-07
Publication Date
2024-11-19
Estimated Expiration
2044-05-07

AI Technical Summary

Technical Problem

The prior art has failed to effectively prepare anti-BP230 monoclonal antibodies, resulting in a lack of specificity and efficiency in the diagnosis and treatment of BP diseases, and immunotherapy may cause BP diseases, lacking rapid and accurate detection methods.

Method used

PBMC was obtained by immunizing the New Zealand white rabbit, sorting and culturing single B cells, analyzing positive clonal sequences, and recombinant expression to obtain high affinity rabbit monoclonal antibodies, which were used to quantitatively detect anti-BP230 autoantibodies in BP patients, providing for detection of BP230 for BP230 detection of BP230 autoantibodies. Protein kit.

Benefits of technology

The obtained anti-BP230 high-affinity monoclonal antibody has high activity, stability and specificity, and can serve as a reference standard for qualitative and quantitative detection, helping to diagnose and study the pathogenic mechanism of BP diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978592A_ABST
    Figure CN118978592A_ABST
Patent Text Reader

Abstract

The invention provides an anti-BP230 high-affinity monoclonal antibody and application thereof. BP230 antigen protein is adopted to carry out multiple times of BP230 protein immunization on an experimental rabbit, and a serum titer test is carried out after immunization; separating high-titer PBMC (peripheral blood mononuclear cells) of spleen tissues and peripheral blood of the rabbits, and carrying out single B cell sorting and culture; rNA is extracted from the positive clone and is reversely transcribed into cDNA, and all antibody VH and VL gene segments in the cDNA are amplified; vH and VL gene segments amplified in vitro are cloned into an expression vector containing a human IgG constant region, and recombinant expression is carried out. Functional verification is carried out on the recombinant antibody through an ELISA method, and finally the humanized monoclonal antibody with good specificity and strong affinity is screened from the recombinant antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of patent application No. 2024105515440 (the filing date of the original application is 2024 / 5 / 7, and the name of the invention is a high-affinity monoclonal antibody against BP230 and its application). Technical Field

[0002] The present invention belongs to the technical field of biomedicine, and specifically relates to an anti-BP230 high-affinity monoclonal antibody and an application thereof. Background Art

[0003] Bullous pemphigoid (BP) is an autoimmune disease that occurs when the immune system attacks the skin and causes blisters. It most often occurs in the elderly aged 60-80 years. The characteristic clinical manifestations of this disease are tense blisters and severe generalized itching symptoms. Histopathologically, hematoxylin and eosin (HE) staining can show subepidermal fissures accompanied by eosinophil infiltration, direct immunofluorescence (DIF) can show linear deposits of autoantibodies and / or complement distributed along the basement membrane zone, and salt-split indirect immunofluorescence (ssIIF) can show autoantibodies and / or complement deposited on the epidermal side.

[0004] The target antigens of autoantibodies in patient sera are BP180 and BP230, also known as BPAG1 and BPAG2, with molecular weights of 180KD and 230KD, respectively. BP230 is a semi-desmosomal glycoprotein in the cytoplasm, and there are three main subtypes: skin subtype (BPAG1-e), neural subtype (BPAG1-n and BPAG1-a), and muscle subtype (BPAG1-b). They have certain homology in molecular structure, each with tissue specificity and different epitopes. Most BP sera show strong positive reactions with different segments of BP230, especially the C-terminus. The N-terminus of BP230 is very important for its binding to semi-desmosomes and its interaction with BP180 and α6β4 integrin β4 subunit. Anti-BP230 antibodies are considered to be secondary products that can aggravate inflammatory responses. Therefore, detecting the level of anti-BP230 antibodies in BP patients is of great significance for assisting clinical diagnosis.

[0005] Monoclonal antibodies are widely used in therapy, diagnosis, and biology due to their high specificity and affinity. Currently, most monoclonal antibodies against human antigens are produced in mice, but many human immunogens cannot stimulate mice to produce antibody responses. Compared with other animal models such as mice and rats, rabbits can respond to a wider range of antigens. The rabbit immune system produces antibody diversity and optimizes affinity through different mechanisms from mice and other rodents. Therefore, rabbits are excellent hosts for monoclonal antibody production. In addition, rabbits are larger in size and have larger spleens, which can produce more antibodies. The preparation of rabbit monoclonal antibodies is an important research work, which can be used in a variety of applications, including immunofluorescence, immunohistochemistry, flow cytometry, protein immunoblotting, and ELISA. In the current state of the art, no anti-BP230 monoclonal antibodies have been prepared.

[0006] BP is a common and stubborn acquired autoimmune disease. The patient's serum contains autoantibodies to hemidesmosome proteins, including anti-BP180 and BP230. The diagnostic criteria for BP include clinical manifestations, histopathology, direct immunofluorescence, indirect immunofluorescence, and specific antibody tests. Different treatment plans are used according to the severity of the disease, mainly relying on glucocorticoids, antibiotics, and immunosuppressants. At present, glucocorticoids are recognized as the first-line drug for the treatment of BP, with significant clinical efficacy, but long-term use can cause a large number of complications, and some serious complications even hinder the use of this drug in some patients in clinical practice. Classic hybridoma technology requires a lot of time and effort to obtain high-affinity antibodies, and subsequent humanization transformation is required, which makes it difficult to obtain human monoclonal antibodies and it is impossible to absolutely quantify the antibody level. Therefore, these treatments lack specificity, have poor efficacy, and have a long course of treatment.

[0007] In addition, immunotherapy in cancer patients can also trigger the occurrence of BP. PD-1 / PD-L1 checkpoint inhibitors are mostly used to treat various solid and hematological malignancies, and are a class of drugs that have been reported to induce BP more frequently in recent years. Most cases develop blisters or bullae within 6-8 months after starting treatment with PD-1 / PD-L1 inhibitors, and a few cases develop mucosal involvement. With the popularization of PD-1 immunotherapy, there will be more and more demand for BP testing in the future. However, there is currently a lack of effective detection methods for how to quickly and accurately diagnose such diseases. Therefore, providing a method for detecting such diseases has important application value. Summary of the invention

[0008] In view of the shortcomings of the prior art, the present invention aims to provide a high-affinity monoclonal antibody against BP230 and its application. The high-affinity monoclonal antibody against BP230 has high activity, good stability and strong specificity, and can be used as a reference standard for qualitative detection of BP230 positivity, and can also quantitatively detect the level of anti-BP230 autoantibodies in BP patients.

[0009] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0010] In the first aspect, the present invention provides a high-affinity anti-BP230 monoclonal antibody, wherein the amino acid sequence of the heavy chain CDR1 of the monoclonal antibody is shown as SEQ ID NO.9, the amino acid sequence of CDR2 is shown as SEQ ID NO.10, and the amino acid sequence of CDR3 is shown as SEQ ID NO.11; the amino acid sequence of the light chain CDR1 of the monoclonal antibody is shown as SEQ ID NO.12, the amino acid sequence of CDR2 is SAS, and the amino acid sequence of CDR3 is shown as SEQ ID NO.13.

[0011] The present invention immunizes New Zealand white rabbits, and performs single B cell sorting and culture on the obtained PBMC. After analyzing the sequence of the positive clone, the recombinant expression is performed, and the obtained high-affinity rabbit monoclonal antibody can quantitatively measure the level of anti-BP230 autoantibodies in BP patients, laying an experimental foundation for studying the pathogenic mechanism of BP, thereby achieving the purpose of diagnosing or treating autoimmune bullous disease.

[0012] Specifically, the present invention performs multiple BP230 protein immunization on experimental rabbits, and performs serum titer test after immunization. The spleen tissue and peripheral blood PBMC of rabbits with high titer are separated, and single B cells are sorted and cultured. RNA is extracted from positive clones and reversely transcribed into cDNA, and all antibody VH and VL gene fragments therein are amplified. The VH and VL gene fragments amplified in vitro are cloned into an expression vector containing a human IgG constant region for recombinant expression. The recombinant antibody is functionally verified by the ELISA method, and finally a humanized monoclonal antibody with good specificity and strong affinity is screened therefrom.

[0013] Preferably, the amino acid sequence of the heavy chain variable region of the monoclonal antibody comprises SEQ ID NO.14, or an amino acid sequence that is at least 80%, 85%, 90% or 95% homologous to SEQ ID NO.14 and has the same or similar functions.

[0014] Preferably, the amino acid sequence of the light chain variable region of the monoclonal antibody comprises SEQ ID NO.16, or an amino acid sequence that is at least 80%, 85%, 90% or 95% homologous to SEQ ID NO.16 and has the same or similar functions.

[0015] Preferably, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.14, and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO.16.

[0016] Preferably, the heavy chain amino acid sequence of the monoclonal antibody comprises SEQ ID NO.15, or an amino acid sequence that is at least 80%, 85%, 90% or 95% homologous to SEQ ID NO.15 and has the same or similar functions.

[0017] Preferably, the light chain amino acid sequence of the monoclonal antibody comprises SEQ ID NO.17, or an amino acid sequence that is at least 80%, 85%, 90% or 95% homologous to SEQ ID NO.17 and has the same or similar functions.

[0018] Preferably, the heavy chain amino acid sequence of the monoclonal antibody is shown as SEQ ID NO.15, and the light chain amino acid sequence of the monoclonal antibody is shown as SEQ ID NO.17.

[0019] In a second aspect, the present invention provides a nucleic acid molecule encoding the anti-BP230 high-affinity monoclonal antibody described in the first aspect.

[0020] In a third aspect, the present invention provides an expression vector, wherein the expression vector contains the nucleic acid molecule described in the second aspect.

[0021] In a fourth aspect, the present invention provides a host cell, wherein the host cell contains at least one copy of the expression vector described in the third aspect, or the nucleic acid molecule described in the second aspect is integrated into the genome of the host cell.

[0022] In a fifth aspect, the present invention provides a composition for detecting BP230 protein, wherein the composition comprises the anti-BP230 high-affinity monoclonal antibody described in the first aspect.

[0023] In a sixth aspect, the present invention provides a kit for detecting BP230 protein in a sample, the kit comprising the anti-BP230 high-affinity monoclonal antibody described in the first aspect and / or the composition for detecting BP230 protein described in the fifth aspect.

[0024] In a specific embodiment, the kit for detecting BP230 protein in a sample is an immunofluorescence detection kit, and the immunofluorescence detection kit comprises the anti-BP230 high-affinity monoclonal antibody described in the first aspect.

[0025] In a specific embodiment, the kit for detecting BP230 protein in a sample is an immunohistochemical detection kit, and the immunohistochemical detection kit comprises the anti-BP230 high-affinity monoclonal antibody described in the first aspect.

[0026] In a specific embodiment, the kit for detecting BP230 protein in a sample is a flow cytometry detection kit, and the flow cytometry detection kit comprises the anti-BP230 high-affinity monoclonal antibody described in the first aspect.

[0027] In a specific embodiment, the kit for detecting BP230 protein in a sample is a protein immunoblotting detection kit, and the protein immunoblotting detection kit comprises the anti-BP230 high-affinity monoclonal antibody described in the first aspect.

[0028] In a specific embodiment, the kit for detecting BP230 protein in a sample is an ELISA detection kit, and the ELISA detection kit comprises the anti-BP230 high-affinity monoclonal antibody described in the first aspect.

[0029] In the seventh aspect, the present invention provides the use of any one or a combination of at least two of the anti-BP230 high-affinity monoclonal antibody described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, the host cell described in the fourth aspect, the composition for detecting BP230 protein described in the fifth aspect, or the kit for detecting BP230 protein in a sample described in the sixth aspect in the preparation of a product for diagnosing bullous pemphigoid.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] The present invention uses the ELISA method to perform functional verification on the recombinant antibodies obtained by screening to verify their specific binding ability with the BP230 antigen. These recombinant antibodies have high activity, good stability, and strong specificity, and can be used as reference standards for qualitative detection of BP230 positivity, and can also quantitatively detect the level of anti-BP230 autoantibodies in BP patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is the SDS-PAGE electrophoresis diagram of the recombinant protein BP230.

[0033] Figure 2 It is the result of the specific binding effect between recombinant antibodies and antigens. DETAILED DESCRIPTION

[0034] The screening and preparation process of the anti-BP230 high-affinity monoclonal antibody described in the present invention is as follows:

[0035] (1) The artificially synthesized BP230 gene was recombined into the expression vector plasmid pET28b to obtain the BP230-pET28b expression vector. The BP230-pET28b expression vector was transfected into BL21 (DE3) competent cells for culture and purified to obtain the BP230 antigen protein.

[0036] (2) The experimental rabbits were immunized with BP230 protein multiple times, and the serum titer was tested after immunization. The spleen tissue and peripheral blood of the immunized rabbits with high serum titers were aseptically separated, and PBMC cells were separated from the two materials using lymphocyte separation fluid. 960 single B cell clones (10×96-well plates, enriched with antigen) were isolated and cultured by B cell staining and flow sorting, and positive clones that specifically recognized the antigen were screened out by ELISA.

[0037] (3)Using SuperScript TM The IV Single Cell / Low-Input cDNA PreAmp Kit (Thermo, catalog number 11752048) reverse transcription kit reversely transcribes the RNA of the single B cell positive clone into cDNA, and amplifies all the antibody VH and VL gene fragments therein. The VH and VL gene fragments amplified in vitro are cloned into the expression vector containing the human IgG constant region through cloning technology for recombinant expression.

[0038] (4) The expressed recombinant antibody was functionally verified using the ELISA method to verify its specific binding ability to the BP230 antigen. Finally, humanized monoclonal antibodies with good specificity and strong affinity were selected.

[0039] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0040] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0041] Example 1 Method for constructing BP230 protein

[0042] The BP230 gene sequence was artificially synthesized, and the BP230 gene was recombined into the expression vector plasmid pET28b to obtain the BP230-pET28b expression vector; the cloning site was NcoI / HindIII, and the amino acid sequence of BP230 was SEQ ID NO.1:

[0043] MGSSHHHHHHSSGLEVLFQGPGSKSTAKDCTFKPDFEMTVKECQHSGELSSRNTGHLHPTPRSPLLRWTQEPQPLEEKWQHRVVEQIPKEVQFQPPGAPLEKEKSQQCYSEYFSQTSTELQITFDETNPITRLSEIEKIRDQALNNSRPPVRYQDNACEMELVKVLTPLEIAKNKQYDMHTEVTTLKQEKNPVPSAEEWMLEGCRASGGLKKGDFLKKGLEPETFQNFDGDHACSVRDDEFKFQGLRHTVTARQLVEAKLLDMRTIEQLRLGLKTVEEVQKTLNKFLTKATSIAGLYLESTKEKISFASAAERIIIDKMVALAFLEAQAATGFIIDPISGQTYSVEDAVLKGVVDPEFRIRLLEAEKAAVGYSYSSKTLSVFQAMENRMLDRQKGKHILEAQIASGGVIDPVRGIRVPPEIALQQGLLNNAILQFLHEPSSNTRVFPNPNNKQALYYSELLRMCVFDVESQCFLFPFGERNISNLNVKKTHRISVVDTKTGSELTVYEAFQRNLIEKSIYLELSGQQYQWKEAMFFESYGHSSHMLTDTKTGLHFNINEAIEQGTIDKALVKKYQEGLITLTELADSLLSRLVPKKDLHSPVAGYWLTASGERISVLKASRRNLVDRITALRCLEAQVSTGGIIDPLTGKKYRVAEALHRGLVDEGFAQQLRQCELVITGIGHPITNKMMSVVEAVNANIINKEMGIRCLEFQYLTGGLIEPQVHSRLSIEEALQVGIIDVLIATKLKDQKSYVRNIICPQTKRKLTYKEALEKADFDFHTGLKLLEVSEPLMTGISSLYYSS。

[0044] The gene sequence is SEQ ID NO.2:

[0045]

[0046] The BP230-pET28b expression vector was transfected into BL21 (DE3) competent cells for culture, and the precipitate was collected for His tag affinity chromatography to obtain the BP230 protein; the purified BP230 also needs to be subjected to SDS-PAGE electrophoresis (polyacrylamide gel electrophoresis) to verify its purity. The SDS-PAGE electrophoresis of the purified BP230 is shown in Figure 1 As shown, the protein size is 90.54 KDa and the purity is greater than 85%.

[0047] Example 2 Preparation of BP230 rabbit monoclonal antibody

[0048] The main instruments used in this example are shown in Table 1, and the main reagents used in this example are shown in Table 2.

[0049] Table 1

[0050] Instrument Name Model / Manufacturer High-speed refrigerated centrifuge Neofuge 15R Biological Safety Cabinets Heal Force Electric constant temperature water bath HHW21.600AⅡ Constant temperature incubator Heal force Automated cell counter Count Star Flow cytometry Beckman Inverted phase contrast microscope Olympus IX71 Shaking incubator ZCZY-AS8

[0051] Table 2

[0052] Reagent name Part Number factory Lymphatic fluid 7111011 Dakota RPMI-1640 350-000-CL WISEENT Fetal bovine serum 10099-141 Gibco L-Glutamine solution 200mM SH30034.01 Hyclone

[0053] 1. Animal immunization

[0054] New Zealand white rabbits (Hubei Experimental Animal Research Center) were selected as immunized animals. During the first immunization, 250 μg of BP230 protein was emulsified with an equal volume of complete Freund's adjuvant and injected at multiple points on the back of the New Zealand white rabbits. The second immunization was performed 15 days later, and 250 μg of BP230 protein was emulsified with an equal volume of incomplete Freund's adjuvant and injected at multiple points on the back of the New Zealand white rabbits. The third immunization was performed 10 days later, and 250 μg of BP230 protein was emulsified with an equal volume of incomplete Freund's adjuvant and injected at multiple points on the back of the New Zealand white rabbits. The fourth immunization was performed 5 days later, and 250 μg of BP230 protein was emulsified with an equal volume of incomplete Freund's adjuvant and injected at multiple points on the back of the New Zealand white rabbits. After four immunizations, the serum titer was determined by ELISA.

[0055] 2. B lymphocyte acquisition

[0056] Take an immune rabbit with high serum test titer, separate spleen tissue aseptically and take peripheral blood. Separate PBMC by Ficoll density gradient centrifugation, wash cells twice with sterile PBS, count suspended cells, and store PBMC in liquid nitrogen for long term.

[0057] 3. B lymphocyte sorting and culture

[0058] 3.1 Resuspend PBMC in PBS and adjust the cell concentration to 1×10 7 cells / mL, add flow cytometry antibodies to stain B cells according to the volume of resuspended cells, add P (Proteintech, Cat No.SA00003-2) and BSA-specific-APC at a ratio of 1:100, pay attention to setting up blank controls and single staining controls, incubate at room temperature in the dark for 30 minutes; wash twice with PBS, and centrifuge at 300g, 4°C for 5 minutes.

[0059] 3.2 Resuspend the cells in PBS and filter the cells with a 100-mesh filter before loading. 5 minutes before loading, add 2% PI to stain and remove dead cells. Use the control to adjust the voltage and set the fluorescence compensation. Use FSC-A / SSC-A to select lymphocytes and use FSC-W / FSC-A to remove adherent cells. Select IgM-negative, antigen-positive, PI-negative B cells.

[0060] 3.3 By flow cytometry, one B cell was added to each well of a 96-well plate containing 100 μL complete 1640 medium (containing 10% FBS, 1% penicillin-streptomycin, 1% glutamine and 2 μg / mL human IL2), the 96-well plate was centrifuged at 300 g for 5 minutes, and cultured at 37°C, 5% CO2 for 7 days.

[0061] 4. Identification of B lymphocytes

[0062] ELISA was performed on the supernatant of cells cultured on the seventh day. The ELISA plate was coated with 100 μL (5 μg / mL) of BP230 antigen per well and incubated at 37°C for 2 hours.

[0063] Discard the liquid in the ELISA plate and wash each well three times with 300μL of 0.05% PBST. Add 300μL of 3% BSA (dissolved in PBS) blocking solution to each well and block at 37℃ for 1.5 hours. Discard the liquid in the ELISA plate and wash each well three times with 300μL of 0.05% PBST. Add 100μL of the twice-diluted supernatant to be tested to each well and incubate at 37℃ for 1 hour. Discard the liquid in the ELISA plate and wash each well three times with 300μL of 0.05% PBST. Add 100μL of secondary antibody (Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) brand: Antibodysystem) diluted with blocking solution to each well and incubate at 37℃ for 45 minutes. Discard the liquid in the ELISA plate and wash each well three times with 300μL of 0.05% PBST. 100 μL TMB was added to each well, incubated at 37°C for 5-10 minutes, and then 50 μL 2M HCl was added to each well to terminate the reaction. The values ​​were read at 450nm-630nm using an ELISA reader. The test results are shown in Table 3.

[0064] Table 3

[0065] Clone number OD450 4-F6 3.73 6-D2 3.4 10-A5 3.09 9-B9 3.79 6-E9 2.92

[0066] 5. Amplification and sequencing analysis of variable regions of positive cloned antibodies

[0067] 5.1 Collect the B cells identified as positive, extract RNA using conventional methods, and then reverse transcribe it into cDNA. Use amplification primers for PCR amplification, and the amplification primers include:

[0068] Antibody heavy chain gene primers:

[0069] Upstream primer (SEQ ID NO. 3) 5′-cagtcggtggaggagtccrgg-3′;

[0070] Downstream primer (SEQ ID NO. 4) 5'-actcgagayggtgaccagggtgcc-3'.

[0071] Antibody light chain kappa chain gene primers:

[0072] Upstream primer (SEQ ID NO. 5) 5′-gagctcgtgmtgacccagactcca-3′;

[0073] Downstream primer (SEQ ID NO. 6) 5'-tttgatttccacattggtgcc-3'.

[0074] Gene primers for the lambda chain of the antibody light chain:

[0075] Upstream primer (SEQ ID NO. 7) 5′-gagctcgtgctgactcagtcgccctc-3′;

[0076] Downstream primer (SEQ ID NO. 8) 5′-gcctgtgacggtcagctgggtccc-3′.

[0077] The PCR amplification program was as follows: a) pre-denaturation at 96°C for 5 minutes; b) denaturation at 96°C for 15 seconds; c) annealing at 58°C for 15 seconds; d) extension at 72°C for 15 seconds; e) final extension at 72°C for 10 minutes; f) storage at 10°C, and steps b to d were repeated 25 times.

[0078] 5.2 The amplified products were subcloned into an expression vector containing the human IgG constant region for sequencing analysis. One of the recombinant antibodies was named ATGM931 (as shown in Table 4).

[0079] Table 4

[0080]

[0081] The heavy chain and light chain sequences of the antibody are shown in Table 5-7:

[0082] Table 5

[0083]

[0084] Table 6

[0085] serial number Heavy chain variable region Heavy chain Light chain variable region Light chain ATGM931 SEQ ID NO.14 SEQ ID NO.15 SEQ ID NO.16 SEQ ID NO.17

[0086] Table 7

[0087]

[0088] Example 3 Functional verification of purified antibodies

[0089] Coat the ELISA plate, add 100 μL (5 μg / mL) of BP230 antigen to each well, and incubate at 37°C for 2 hours. Discard the liquid in the ELISA plate, and wash each well three times with 300 μL of 0.05% PBST. Add 300 μL of 3% BSA (dissolved in PBS) blocking solution to each well, and block at 37°C for 1.5 hours. Discard the liquid in the ELISA plate, and wash each well three times with 300 μL of 0.05% PBST. Add 100 μL of gradient diluted recombinant antibody to each well, and incubate at 37°C for 1 hour. Discard the liquid in the ELISA plate, and wash each well three times with 300 μL of 0.05% PBST. Add 100 μL of secondary antibody (Goat Anti-Human IgG PolyclonalAntibody, HRP (PHB96431), brand: Antibodysystem) diluted with blocking solution to each well, and incubate at 37°C for 45 minutes. Discard the liquid in the ELISA plate and wash each well three times with 300 μL of 0.05% PBST. Add 100 μL of TMB to each well and incubate at 37°C for 5-10 minutes, then add 50 μL of 2M HCl to each well to terminate the reaction. Use an ELISA reader to read the values ​​at 450nm-630nm. The test results are shown in Figure 2 .from Figure 2 It can be seen that the screened humanized anti-BP230 monoclonal antibody has a strong specific binding ability with BP230.

[0090] In summary, the monoclonal antibodies screened in the present invention have strong specific binding ability with BP230 antigen, and the obtained recombinant antibodies have high activity, good stability, and strong specificity. They can be used as a reference standard for qualitative detection of BP230 positivity, and can also be used to quantitatively detect the level of anti-BP230 autoantibodies in BP patients.

[0091] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. An anti-BP230 high-affinity monoclonal antibody, characterized in that: The amino acid sequence of the heavy chain CDR1 of the monoclonal antibody is shown in SEQ ID NO.9, the amino acid sequence of CDR2 is shown in SEQ ID NO.10, and the amino acid sequence of CDR3 is shown in SEQ ID NO.11; the amino acid sequence of the light chain CDR1 of the monoclonal antibody is shown in SEQ ID NO.12, the amino acid sequence of CDR2 is SAS, and the amino acid sequence of CDR3 is shown in SEQ ID NO.

13.

2. The anti-BP230 high-affinity monoclonal antibody according to claim 1, characterized in that: The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.14; the amino acid sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.

16.

3. The anti-BP230 high-affinity monoclonal antibody according to claim 1, characterized in that: The heavy chain amino acid sequence of the monoclonal antibody is shown in SEQ ID NO.15; the light chain amino acid sequence of the monoclonal antibody is shown in SEQ ID NO.

17.

4. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the anti-BP230 high-affinity monoclonal antibody according to any one of claims 1 to 3.

5. An expression vector, characterized in that: The expression vector contains the nucleic acid molecule according to claim 4.

6. A host cell, characterized in that The host cell contains at least one copy of the expression vector of claim 5, or the nucleic acid molecule of claim 4 is integrated into the genome of the host cell.

7. A composition for detecting BP230 protein, characterized in that: The composition comprises the anti-BP230 high-affinity monoclonal antibody according to any one of claims 1 to 3.

8. A kit for detecting BP230 protein in a sample, characterized in that: The kit comprises the anti-BP230 high-affinity monoclonal antibody according to any one of claims 1 to 3 and / or the composition for detecting BP230 protein according to claim 7.

9. Use of any one of the anti-BP230 high-affinity monoclonal antibodies according to any one of claims 1 to 3, the nucleic acid molecule according to claim 4, the expression vector according to claim 5, the host cell according to claim 6, the composition for detecting BP230 protein according to claim 7, or the kit for detecting BP230 protein in a sample according to claim 8, or a combination of at least two thereof in the preparation of a product for diagnosing bullous pemphigoid.

Citation Information

Patent Citations

  • Antigenic epitope polypeptide of bullous pemphigoid BP230 IgE antibody and application of epitope polypeptide

    CN110437326A

  • Diagnostic kit for bullous pemphigus

    CN116223807A